Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Bactrim DS
sulfamethoxazole-trimethoprim (SMZ)
Septra
Sulfamethoxazole
Septra DS
Sulfamethoxazole Tab 500mg
Teva-trimel DS
Nu-cotrimox Tab 400/80mg
Sulfamethoxazole and Trimethoprim Injection, BP
SULFAMETHOXAZOLE and TRIMETHOPRIM
Bactrim
Septra Injection
Trisulfa DS Tab
Sulfatrim
Teva-trimel
Protrin Tab
Sulfamethoxazole and Trimethoprim Tablets
Sulfamethoxazole and Trimethoprim for Injection, USP
Septra DS Tablets
Apo-sulfatrim Oral Suspension
Septra Grape
Roubac Tab 160/800
Sulfamethoxazole and Trimethoprim
Nu-cotrimox Sus 40/8mg/ml
Protrin Df Tab
Roubac Tab 80/400
Trisulfa Tab
Bactrim DS Roche Tab
Sulfatrim DS
Sulfamethoxazole and Trimethoprim DS
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Nu-cotrimox-DS Tab 800/160mg
Bactrim Roche Inj
Trisulfa S Suspension
Septra Pediatric Suspension
Sulfamethox-TMP DS
Bactrim Roche Tab
Sulfamethoxazole and Trimethoprim Double Strength
Riva-sep DS
Sulfatrim Pediatric
Sulfameth/Trimeth-DS
Apo Sulfamethoxazole Tab 500mg
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682